Senator NELSON. Our next witness will be Dr. Lloyd C. Miller, director of the Revision and Acting Secretary of U.S. Pharmacopeial Convention.

Dr. Miller, we appreciate very much your taking the time to come over this afternoon. You may present your statement in any fashion that suits you. We may have a question or two, if you don't mind being interrupted. I think there is going to be a roll call vote in the Senate before very long, and it may require me to absent myself temporarily.

STATEMENT OF LLOYD C. MILLER, PH. D., DIRECTOR OF REVISION AND ACTING SECRETARY OF THE U.S. PHARMACOPEIAL CONVENTION, INC., NEW YORK, N.Y.

Dr. MILLER. Thank you very much, Senator Nelson. I appreciate greatly the opportunity to come here. I will preface my remarks by putting into the record a brief comment upon my training and background.

My name is Lloyd C. Miller, and I reside in Westchester County, N.Y. My advanced academic training, leading to a Ph. D. in 1933 from the University of Rochester, was in biochemistry and pharmacology. My experience has included 8 years on the headquarters staff of the Food and Drug Administration and 9 years as a research investigator in the pharmaceutical industry. Since 1950 I have served as director of revision of the U.S. Pharmacopeial Convention, an independent, nonprofit scientific organization devoted to providing standards of strength and purity for drugs. Since 1962, I have served also as acting secretary of the USP Convention.

I am a member of several scientific societies. I will mention only the American Society for Pharmacology and Experimental Therapeutics. It is an organization in which membership is by invitation.

In the present discussion of drug prices and drug quality, there is an acute need for bringing proper perspective to certain aspects of standards of drug quality. In view of the frequent mention of the standards of the U.S. Pharmacopeia in the discussion, we propose to explain briefly how these standards come into being and how they serve to determine the quality of drugs generally.

In 1960, we presented a rather comprehensive statement on the pharmacopeia to the Senate Subcommittee on Antitrust and Monopoly which was holding hearings under chairmanship of the late Senator Kefauver. On the assumption that the record of those hearings is readily available, our remarks today are intended mainly to update and amplify the 1960 statement.[1] Some recapitulation may be helpful, however. We wish also to correct some rather serious erroneous impressions that have been created of late to the effect that the USP standards are too lax, too few, or quite unequal to the task for which they are intended. An erroneous impression seems also to have gained credence that the USP is dominated by the pharmaceutical industry; the falsity of that, too, will be shown.

Senator NELSON. Do you know of any witness who has made that statement before our committee?

---

[1] See p. 1161, pt. 21, hearings before the Subcommittee on Antitrust and Monopoly of the Committee on the Judiciary, U.S. Senate, 86th Congress.